Results of the study with the blood test Epi proColon® is now published in the journal of “Cancer Treatment and Research Communications”. Read more
Molecular Pathology Laboratory Network, custom services for #oncologists #pathologists;
experience in #flowcytometry…
MPLN follows a development process for laboratory developed tests. A phased approach is useful for organizing and assessing the performance of an assay.
Concordance of three different PD-L1 diagnostic assays (1)
MPLN’s PD-L1 assay, the Ventana SP263, was included in the concordance study of three PD-L1 Diagnostic Tests by AstraZeneca and results reported at Read more
A recent article by Anne Paxton in CAP Today (November 2016) discusses the FDA approval of the Epigenomics Epi proColon® assay for colon cancer screening. MPLN's Dr. Nicholas Potter explains the series of events and the study data from…